Rallybio
RLYB
53 hedge funds and large institutions have $402M invested in Rallybio in 2022 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 15 reducing their positions, and 3 closing their positions.
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
93% more capital invested
Capital invested by funds: $209M → $402M (+$193M)
13% more funds holding
Funds holding: 47 → 53 (+6)
0.05% more ownership
Funds ownership: 10.76% → 10.81% (+0.05%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
7% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
CHI Advisors
New York
|
+$2.16M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.14M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$756K |
| 4 |
BlackRock
New York
|
+$623K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$258K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$2.12M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$1.25M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$157K |
| 4 |
Millennium Management
New York
|
-$137K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$77K |
RLYB Hedge Fund Activity: Q3 2022 in Review
53 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Rallybio (RLYB) for Q3 2022, worth a combined $402M — up 93% from $209M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new RLYB positions and 3 closed out — a net gain of 6 holders — while 14 added to existing stakes and 15 trimmed.
The largest buyer was CHI Advisors, opening a new position worth an estimated $2.16M. The largest seller was Tekla Capital Management, cutting an estimated $2.12M.
- 53 institutional investors held Rallybio (RLYB) as of Q3 2022, up from 47 in Q2 2022.
- Funds reported $402M of Rallybio stock for Q3 2022, up 93% quarter-over-quarter.
- 9 funds opened new Rallybio positions in Q3 2022 and 3 closed out, a net change of +6 holders.
- The largest Rallybio buyer in Q3 2022 was CHI Advisors, an estimated $2.16M added.
- The largest Rallybio seller in Q3 2022 was Tekla Capital Management, an estimated $2.12M sold.
Based on aggregated 13F filings for Q3 2022.